Navigation Links
Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines
Date:4/15/2008

-Researchers Now Able to Detect a Single Cancer Cell Through In Vivo

Imaging-

HOPKINTON, Mass., April 15 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP) today introduced Bioware(R) Ultra cell lines, a range of ultra bright light producing tumor cell lines created specifically for in vivo imaging applications. Bioware Ultra cell lines are 10 to 100 times brighter than cell lines created using traditional methods, which allows researchers, for the first time ever, to detect a single cancer cell in an animal via non-invasive in vivo imaging.

Visualizing and tracking tumor progression in vivo is critical to better understanding how therapeutic treatments impact disease. In vivo imaging provides researchers with the ability to recognize tumor growth and behaviors at the cellular level within living animals. By tagging a tumor with the gene for luciferase, the same gene that allows a firefly to glow, the tumor can produce light that can be monitored using Caliper's highly sensitive IVIS imaging systems. As the disease progresses and reacts to specific compounds, researchers can measure tumor growth and evaluate the efficacy of compounds in real time. This ability to track disease progression in vivo offers a more conclusive understanding of how potential drugs will react in and impact humans.

Increasing the brightness of tumor producing cell lines significantly improves researchers' ability to monitor early tumor behavior and detect micrometastases sooner. Caliper's Bioware Ultra light producing cell lines incorporate the enhanced luc2 gene from Promega. The luc2 gene, an optimized version of luciferase for expression in mammalian cells, creates intensified visible li
'/>"/>

SOURCE Caliper Life Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. APIC Statement on Need for Increased Prevention Measures for Healthcare-Associated Infections (HAIs)
2. Kiwa Bio-Tech Animal Feed Volume Increased 25% in Fourth Quarter of 2007
3. Novo Nordisk Increased Operating Profit by 11% in the First Nine Months of 2007 Based on a 9% Sales Increase and an Improved Gross Margin
4. MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research
5. Sirion Therapeutics Highlights Pivotal Trial Results of Durezol(TM) at the American Society of Cataract and Refractive Surgery Annual Symposium
6. Light Sciences Oncology Appoints David P. Holveck to Its Board of Directors
7. Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
8. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
9. ChanTest to Highlight Most-Comprehensive Range of Ion Channel Profiling Screens and Consultation Services at 14th Annual SBS Conference, Booth 1104
10. ChanTest to Highlight Expanded Ion Channel Testing Services for Preclinical Safety at ToxExpo, Including the Worlds Largest Catalog of Validated Ion Channels, Booth 2504
11. Helix BioPharma reports Q2 2008 highlights, financial results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)..., Nov. 27 Cromoz Inc., located in ...e carbon nanotube-based cancer drug delivery syste...notubes, which have functional groups on the walls...s developed in partnership with the Indian Institu...s serves as a drug delivery vehicle with the abili...
(Date:11/26/2009)... new generation of ultrasmall transistors and more...led semiconducting nanowires are closer to reality...ue University and the University of California at ...to create nanowires with layers of different mater... which is a critical requirement for making effici...
(Date:11/25/2009)...ssador to Speak at Economic Club of Canada , ...er 25, 2009 -- Ambassador to Speak at Economic Clu...bassador for International Investment, and Chairma...a biography of David Appia go to www.investinfran...e to meet with press to discuss recent pro-busines...
(Date:11/25/2009)..., Nov. 25 /PRNewswire-Asia/ -- Sinovac Biotech Ltd...ines, announced today that it executed,a joint ven...Vaccine,Technology Co., Ltd. (Sinovac Dalian). The...ize human-use vaccines. Sinovac will contribute it...rcializing world-class vaccines; the,other party w...
Breaking Biology Technology:North Carolina Based Cromoz Inc. Launches Carbon Nanotechnology for Target Drug Delivery System in Cancer Treatment in Hyderabad, India 2Nanowires key to future transistors, electronics 2Nanowires key to future transistors, electronics 3French Ambassador for International Investment to Visit Toronto December 11 2Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 2Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 3
...rta and the National Research Council,s National I... an approach that is leading to improved performan...lls). The development of inexpensive, mass-produce...st for many of the world,s scientists and engineer...ra-high purity silicon and other materials normall...
...ates Anti-Tumor Activity Across Doses and Endpoint... Patients - , , - Data To Be Presented at ASCO,s ...vation to Host Conference Call and Webcast Present...tern Time - , , SAN FRANCISCO, Feb. 25 Medivati...sentation of new efficacy and safety data from an ...
...harmaceuticals Inc.,(Nasdaq: TRBN ) today announ...cent, or 25 employees, and a corporate restructuri...apital markets and the global economy, Trubion,is ...lign its current,resources with its strongest near...for long-term sustainability and success. , Fo...
Other Biology Technology:University of Alberta and NINT researchers make solar energy breakthrough 2Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients 2Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients 3Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients 4Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients 5Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring 2Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring 3Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring 4
(Date:11/30/2009)... December 2009 print issue of The FASEB Journal ...r their fertility that women have had since the 19...where androgenic hormones work in the testis to co...This opens a promising avenue for the development ...ope to those who cannot have children because of l...
(Date:11/30/2009)...dioactive gas that is produced by the radioactive ...cay and is found in trace amounts naturally in nea...uilding materials, plants, animals, and the human ... amount of radiation that would be emitted by rado...he units are picocuries per liter (pCi/L). The Ame...
(Date:11/26/2009)...ed deer have been caught in the hunters, sights fo...than decorative. They are lethal weapons that stag...The University of York, UK, has been intrigued by ...century and has become fascinated by the mechanica...laboration with Tomas Landete-Castillejos at the U...
Breaking Biology News(10 mins):Health Physics Society recommends considering action for indoor radon below current guidelines 2Tough yet stiff deer antler is materials scientist's dream 2 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 1 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 2 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 3 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 4 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 5 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 6 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 7 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 8 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 9Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease 3B Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver 4745 1Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease 3B Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver 4745 2Highlights of Economic and Business Growth in the Tampa Bay Region 28News Briefs 29 52073 1Highlights of Economic and Business Growth in the Tampa Bay Region 28News Briefs 29 52073 2Highlights of Economic and Business Growth in the Tampa Bay Region 28News Briefs 29 52073 3Highlights of Economic and Business Growth in the Tampa Bay Region 28News Briefs 29 52073 4
... written book describes hundreds of well-known and...rporate leaders, and literary greats who used or a...esidents, seven popes, Sir William Osler, J.D. Roc...re among those famous people who were known to hav...ngly is the evidence of Charles Darwins use of hom...
...o the way in which parasites interact with each ot...e likely to break out. , A group of scientists i...r of infectious parasites in rabbits. The findings...ssfully when infectious cyclical diseases in human...niversitys School of Biosciences, University of St...
...ses, such as when to multiply, are often regulated... of interactions between proteins. North Carolina ...y in which a specific protein-protein interaction ... off, leading to uncontrolled cell proliferation ...ished in the December 2007 edition of the Cell Pre...
Other Biology News:The surprising story of Charles Darwin and his homeopathic doctor 2The surprising story of Charles Darwin and his homeopathic doctor 3Can interacting pathogens explain disease patterns? 2Why the switch stays on 2Why the switch stays on 3
X-gal from BioPioneer
Angiogenesis Tube formation Assay Kit from Upstate
Monkey IL-6 ELISPOT Kit, With white/opague microtiter plates from Cell Sciences
Histone Deacetylase Radiometric (3H) Assay Kit from Upstate
Biology Products: